
Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.
The number of biosimilars in rheumatology is growing. Test your knowledge of biosimilars with this quiz.
Is the following statement true or false?
A manufacturer developing a biosimilar will need to demonstrate that its product is highly similar to the reference product in terms of purity, chemical identity, and bioactivity, but will not need to undertake any clinical trials to demonstrate safety and efficacy.






